1. Home
  2. GXAI vs AIMD Comparison

GXAI vs AIMD Comparison

Compare GXAI & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gaxos.ai Inc.

GXAI

Gaxos.ai Inc.

HOLD

Current Price

$1.17

Market Cap

8.8M

Sector

N/A

ML Signal

HOLD

AIMD

Ainos Inc.

HOLD

Current Price

$1.78

Market Cap

10.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GXAI
AIMD
Founded
2021
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.8M
10.2M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
GXAI
AIMD
Price
$1.17
$1.78
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
171.2K
23.9K
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$694,278.00
$113,037.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
23205.74
178.19
52 Week Low
$1.00
$1.61
52 Week High
$3.36
$5.00

Technical Indicators

Market Signals
Indicator
GXAI
AIMD
Relative Strength Index (RSI) 51.70 35.05
Support Level $1.02 $1.61
Resistance Level $1.25 $1.95
Average True Range (ATR) 0.07 0.12
MACD 0.03 -0.00
Stochastic Oscillator 73.91 26.32

Price Performance

Historical Comparison
GXAI
AIMD

About GXAI Gaxos.ai Inc.

Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.

About AIMD Ainos Inc.

Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.

Share on Social Networks: